Free Trial
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Adial Pharmaceuticals logo
$0.39 +0.01 (+1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$0.38 -0.01 (-1.75%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Key Stats

Today's Range
$0.38
$0.39
50-Day Range
$0.23
$0.63
52-Week Range
$0.22
$1.30
Volume
354,324 shs
Average Volume
4.00 million shs
Market Capitalization
$8.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

Adial Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

ADIL MarketRank™: 

Adial Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Adial Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Adial Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adial Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adial Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adial Pharmaceuticals has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Adial Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    16.82% of the float of Adial Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adial Pharmaceuticals has recently increased by 919.93%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Adial Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Adial Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.82% of the float of Adial Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adial Pharmaceuticals has recently increased by 919.93%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Adial Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Adial Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 8 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.26% of the stock of Adial Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 16.41% of the stock of Adial Pharmaceuticals is held by institutions.

  • Read more about Adial Pharmaceuticals' insider trading history.
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADIL Stock News Headlines

Equities Analysts Offer Predictions for ADIL Q3 Earnings
Adial Hails Senate Moves on Trials
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
Adial Pharmaceuticals Enters New Sales Agreement
Adial Pharmaceuticals Inc.
See More Headlines

ADIL Stock Analysis - Frequently Asked Questions

Adial Pharmaceuticals' stock was trading at $1.01 on January 1st, 2025. Since then, ADIL stock has decreased by 61.5% and is now trading at $0.3888.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04.

Shares of Adial Pharmaceuticals reverse split on the morning of Monday, August 7th 2023.The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and GE Aerospace (GE).

Company Calendar

Last Earnings
8/13/2025
Today
8/28/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADIL
CIK
1513525
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$8.00
Potential Upside/Downside
+1,999.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.20 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-191.31%
Return on Assets
-153.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.02
Quick Ratio
5.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.26 per share
Price / Book
1.47

Miscellaneous

Outstanding Shares
21,830,000
Free Float
20,898,000
Market Cap
$8.32 million
Optionable
No Data
Beta
1.00

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ADIL) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners